Addex Therapeutics Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.3M
- Price
- $4.94
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.10%
- Volume
- 7.3M
About
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Quick stats
Shares outstanding1.3M
Computed float578.7K
Float / shares45.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001574232
AI Summary
AI-generated1/22
minorneutraloperations update
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Addex announced the publication of preclinical data in the International Journal of Neuropsychopharmacology, demonstrating that ADX71743 modulates sleep-wake regulation and stress neurochemistry in animal models.
ADX71743 is now being advanced by Neurosterix, a company launched by Addex and Perceptive Advisors in 2024; Addex holds a 20% equity interest in the spin-out.
Addex continues to independently develop its lead candidate dipraglurant for brain injury recovery and a GABAB PAM for chronic cough, while partner Indivior advances a GABAB PAM for substance use disorders.